Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
National Institutes of Health Clinical Center (CC)
Xuanwu Hospital, Beijing
Assistance Publique - Hôpitaux de Paris
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Huashan Hospital
The University of Texas Health Science Center at San Antonio
Azienda Sanitaria dell'Alto Adige
University of Alabama at Birmingham
Coherence Neuro Australia Pty Limited
M.D. Anderson Cancer Center
Washington University School of Medicine
Tetragon Biosciences Ltd
Washington University School of Medicine
Washington University School of Medicine
NYU Langone Health
Yale University
Baptist Health South Florida
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
NRG Oncology
Trogenix ltd
Maastricht University Medical Center
GCS Ramsay Santé pour l'Enseignement et la Recherche
Tianjin Medical University Cancer Institute and Hospital
Ipsen
University of Aberdeen
Weill Medical College of Cornell University
Vanderbilt-Ingram Cancer Center
Case Comprehensive Cancer Center
The Cooper Health System
Assistance Publique - Hôpitaux de Paris
Cancer Research UK
M.D. Anderson Cancer Center
Exelixis
Lantern Pharma Inc.
Assistance Publique - Hôpitaux de Paris
Hospices Civils de Lyon
University of Alabama at Birmingham
Duke University
Northwestern University
Clinica Universidad de Navarra, Universidad de Navarra
Jonsson Comprehensive Cancer Center
King's College Hospital NHS Trust
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of California, San Francisco
Medical University of Warsaw
Insel Gruppe AG, University Hospital Bern
VA Office of Research and Development